

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021205 001	ABACAVIR SULFATE;TRIZIVIR	6417191	MAR 28, 2016	U-248		
021449 001	ADEFOVIR DIPIVOXIL;HEPSERA	6417191*PED 6451340 4808716 5663159	SEP 28, 2016 JUL 23, 2018 APR 25, 2006 SEP 02, 2014	U-248 U-470 U-470	NCE	SEP 20, 2007
>ADD>	020503 001	ALBUTEROL SULFATE;PROVENTIL-HFA	4724233 5695743 6352684	APR 21, 2006 JUL 06, 2010 NOV 28, 2009	U-470	
021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	OCT 15, 2013		NP	JUN 11, 2005
021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	OCT 15, 2013		NP	JUN 11, 2005
021212 001	ALPROSTADIL;CAVERJECT				NP	JUN 11, 2005
021212 002	ALPROSTADIL;CAVERJECT				NP	JUN 11, 2005
020364 005	AMLODIPINE BESYLATE;LOTREL	4410520	AUG 11, 2003		NS	JUN 20, 2005
		4572909	JUL 31, 2006			
		4879303	MAR 25, 2007			
		6162802	DEC 19, 2017	U-367		
021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10	6322819	NOV 27, 2018			
021303 006	AMPHETAMINE ASPARTATE;ADDERALL XR 15	6322819	NOV 27, 2018		NDF	OCT 11, 2004
021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20	6322819	NOV 27, 2018			
021303 004	AMPHETAMINE ASPARTATE;ADDERALL XR 25	6322819	NOV 27, 2018		NDF	OCT 11, 2004
021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30	6322819	NOV 27, 2018			
021303 005	AMPHETAMINE ASPARTATE;ADDERALL XR 5	6322819	NOV 27, 2018		NDF	OCT 11, 2004
>ADD>	011522 007	AMPHETAMINE ASPARTATE;ADDERALL 10	6384020	JUL 06, 2020		
>ADD>	011522 012	AMPHETAMINE ASPARTATE;ADDERALL 12.5	6384020	JUL 06, 2020		
>ADD>	011522 013	AMPHETAMINE ASPARTATE;ADDERALL 15	6384020	JUL 06, 2020		
>ADD>	011522 008	AMPHETAMINE ASPARTATE;ADDERALL 20	6384020	JUL 06, 2020		
>ADD>	011522 010	AMPHETAMINE ASPARTATE;ADDERALL 30	6384020	JUL 06, 2020		
>ADD>	011522 009	AMPHETAMINE ASPARTATE;ADDERALL 5	6384020	JUL 06, 2020		
>ADD>	011522 011	AMPHETAMINE ASPARTATE;ADDERALL 7.5	6384020	JUL 06, 2020		
020541 001	ANASTROZOLE;ARIMIDEX				I-363	SEP 05, 2005
020883 001	ARGATROBAN;ARGATROBAN	5925760	AUG 04, 2017		I-352	APR 03, 2005
>ADD>	021436 001	ARIPIPRAZOLE;ABILIFY			NCE	NOV 15, 2007
>ADD>	021436 002	ARIPIPRAZOLE;ABILIFY			NCE	NOV 15, 2007
>ADD>	021436 003	ARIPIPRAZOLE;ABILIFY			NCE	NOV 15, 2007
>ADD>	021436 004	ARIPIPRAZOLE;ABILIFY			NCE	NOV 15, 2007
>ADD>	021436 005	ARIPIPRAZOLE;ABILIFY			NCE	NOV 15, 2007
>ADD>	021436 006	ARIPIPRAZOLE;ABILIFY			NCE	NOV 15, 2007
020702 001	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
					I-350	OCT 18, 2005
					PED	APR 18, 2006
020702 002	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
					I-350	OCT 18, 2005
					PED	APR 18, 2006
020702 003	ATORVASTATIN CALCIUM;LIPITOR				D-77	APR 22, 2005
					I-350	OCT 18, 2005
					PED	APR 18, 2006

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020702 004	ATORVASTATIN CALCIUM;LIPITOR				D-77 I-350	APR 22, 2005 OCT 18, 2005
020911 002	BECLOMETHASONE DIPROPIONATE;QVAR 40	6352684	NOV 28, 2009		PED NP	APR 18, 2006 SEP 15, 2003
020911 001	BECLOMETHASONE DIPROPIONATE;QVAR 80	6352684	NOV 28, 2009		NPP NP	MAY 10, 2005 SEP 15, 2003
021055 001	BEXAROTENE;TARGRETIN	5962731	OCT 05, 2016	U-475		
021275 001	BIMATOPROST;LUMIGAN	6403649	SEP 21, 2012	U-446		
>ADD> 020873 001	BIVALIRUDIN;ANGIOMAX	5196404	MAR 23, 2010			
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NPP PED	DEC 20, 2004 JUN 20, 2005
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6465464	JUN 28, 2015	U-394	NPP	DEC 20, 2004
		6465464*PED	DEC 28, 2015	U-394	PED	JUN 20, 2005
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6465464	JUN 28, 2015	U-395	NPP	DEC 20, 2004
		6465464*PED	DEC 28, 2015	U-395	PED	JUN 20, 2005
021324 001	BUDESONIDE;ENTOCORT EC	5643602	JUL 01, 2014		NP	OCT 02, 2004
		5643602*PED	JAN 01, 2015		PED	APR 02, 2005
020441 002	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
		4668218*PED	OCT 11, 2006			
		4907583*PED	SEP 13, 2007			
020441 003	BUDESONIDE;PULMICORT	4668218	APR 11, 2006			
		4907583	MAR 13, 2007			
		4668218*PED	OCT 11, 2006			
		4907583*PED	SEP 13, 2007			
020929 001	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
020929 002	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
>ADD> >ADD> 020929 003	BUDESONIDE;PULMICORT RESPULES	4787536	FEB 27, 2006		NDF	AUG 08, 2003
		4787536*PED	AUG 27, 2006		PED	FEB 08, 2004
020746 001	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		NDF	OCT 01, 2002
		6291445*PED	OCT 29, 2017		M-22	OCT 26, 2004
					PED	APR 26, 2005
					PED	APR 01, 2003
020746 002	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017		NDF	OCT 01, 2002
		6291445*PED	OCT 29, 2017		M-22	OCT 26, 2004
					PED	APR 26, 2005
					PED	APR 01, 2003
020733 001	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE				NDF	OCT 08, 2005
>ADD>					ODE	OCT 08, 2009
>ADD> 020733 002	BUPRENORPHINE HYDROCHLORIDE;SUBOXONE				NDF	OCT 08, 2005
					ODE	OCT 08, 2009

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020732 002	BUPRENORPHINE HYDROCHLORIDE;SUBUTEX				NDF	OCT 08, 2005
>ADD>					ODE	OCT 08, 2009
020732 003	BUPRENORPHINE HYDROCHLORIDE;SUBUTEX				NDF	OCT 08, 2005
>ADD>					ODE	OCT 08, 2009
020358 004	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR	5358970	AUG 12, 2013		M-10	JUN 11, 2004
		5427798	AUG 12, 2013			
		5731000	AUG 12, 2013			
		5763493	AUG 12, 2013			
		RE33994	AUG 18, 2004			
018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
					PED	JAN 19, 2005
					W	JUL 19, 2004
					W	JAN 19, 2005
020954 001	BUSULFAN;BUSULFEX	5430057	SEP 30, 2013	U-263	ODE	FEB 04, 2006
		5559148	MAY 24, 2015	U-264	NDF	FEB 04, 2002
		5430057*PED	MAR 30, 2014	U-263	PED	AUG 04, 2002
		5559148*PED	NOV 24, 2015	U-264	PED	AUG 04, 2006
021408 001	BUTENAFINE HYDROCHLORIDE;MENTAX-TC				NP	OCT 17, 2005
019881 001	BUTOCONAZOLE NITRATE;GYNAZOLE-1	5266329	NOV 30, 2010	U-457		
		4551148	NOV 05, 2002			
020838 001	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
020838 002	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
020838 003	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
020838 004	CANDESARTAN CILEXETIL;ATACAND	5196444	JUN 04, 2012	U-3	M-21	SEP 13, 2005
021093 001	CANDESARTAN CILEXETIL;ATACAND HCT	5196444	JUN 04, 2012	U-3		
021093 002	CANDESARTAN CILEXETIL;ATACAND HCT	5196444	JUN 04, 2012	U-3		
021222 001	CEFDITOREN PIVOXIL;SPECTRACEF	4839350	JUN 13, 2006		I-364	AUG 21, 2005
		4918068	JUN 13, 2006			
		5958915	OCT 14, 2016			
020998 003	CELECOXIB;CELEBREX	5466823	NOV 30, 2013		I-284	DEC 23, 2002
		5563165	NOV 30, 2013		NCE	DEC 31, 2003
		5760068	JUN 02, 2015	U-19	I-338	OCT 17, 2004
		5760068	JUN 02, 2015	U-299		
		5972986	OCT 14, 2017	U-299		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020740 001	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
020740 002	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
020740 003	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
020740 004	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
020740 005	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
020740 006	CERIVASTATIN SODIUM;BAYCOL	5006530	JUN 26, 2011			
019835 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
019835 002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
020346 001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007		NPP	OCT 21, 2005
		4525358*PED	DEC 25, 2007		PED	APR 21, 2006
021555 001	CHLORHEXIDINE GLUCONATE;CHLORAPREP ONE-STEP				NP	OCT 07, 2005
020369 001	CIPROFLOXACIN HYDROCHLORIDE;CILOXAN	4670444	DEC 09, 2003	U-223		
020822 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 002	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020822 003	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
021046 001	CITALOPRAM HYDROBROMIDE;CELEXA				NCE	JUL 17, 2003
					PED	JAN 17, 2004
020839 001	CLOPIDOGREL BISULFATE;PLAVIX	6429210	JUN 10, 2019		I-349	FEB 27, 2005
021141 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6433026	JUN 10, 2014			
021176 001	COLESEVELAM HYDROCHLORIDE;WELCHOL	6433026	JUN 10, 2014			
021165 001	DESLOMATADINE;CLARINEX	6100274	JUL 07, 2019			
021312 001	DESLOMATADINE;CLARINEX				NCE	DEC 21, 2006
075863 001	DESOGESTREL;KARIVA				PC	JUN 04, 2002
021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	6355656	DEC 04, 2015			
021191 001	DIMYRISTOYL LECITHIN;IMAGENT	6280704	JUL 30, 2013		NCE	MAY 31, 2007
		6280705	JUL 30, 2013			
		6287539	JUL 30, 2013			
		5605673	FEB 25, 2014			
		5626833	MAY 16, 2014	U-458		
		5639443	JUN 17, 2014			
		5695741	DEC 09, 2014	U-458		
		5720938	FEB 24, 2015			
		5798091	AUG 25, 2015	U-458		
021168 001	DIVALPROEX SODIUM;DEPAKOTE ER	6419953	DEC 18, 2018			
021168 002	DIVALPROEX SODIUM;DEPAKOTE ER	4913906	APR 03, 2007		NP	AUG 04, 2003
		4988731	JAN 29, 2008			
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6372760	MAR 31, 2019			

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6372760	MAR 31, 2019			
020862 001	DOXERCALCIFEROL;HECTOROL	5602116	FEB 11, 2014	U-278		
		5707980	AUG 17, 2010	U-278		
		5861386	AUG 02, 2008	U-278		
		5869473	AUG 02, 2008	U-278		
021027 001	DOXERCALCIFEROL;HECTOROL	5602116	FEB 11, 2014	U-321		
		5707980	AUG 17, 2010	U-321		
021098 001	DROSPIRENONE;YASMIN	5569652	OCT 29, 2013	U-1		
021319 001	DUTASTERIDE;AVODART	5565467	OCT 15, 2013			
		5846976	DEC 08, 2015	U-476		
		5998427	OCT 15, 2013	U-477		
020972 001	EFAVIRENZ;SUSTIVA	6238695	APR 06, 2019			
020972 002	EFAVIRENZ;SUSTIVA	6238695	APR 06, 2019			
020972 003	EFAVIRENZ;SUSTIVA	6238695	APR 06, 2019			
021360 001	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
		5633169	SEP 02, 2014	U-248		
		5811423	AUG 07, 2012	U-256		
021360 002	EFAVIRENZ;SUSTIVA	5519021	MAY 21, 2013			
		5663169	SEP 02, 2014	U-248		
		5811423	AUG 07, 2012	U-256		
020796 001	ENTACAPONE;COMTAN	5446194	AUG 29, 2012			
		5135950	OCT 31, 2010			
		4963590	NOV 27, 2007			
		5112861	MAY 12, 2009			
021437 001	EPLERENONE;INSPIRA	6410054	DEC 08, 2019	U-3	NCE	SEP 27, 2007
		6410524	NOV 05, 2019	U-467		
		4559332	APR 09, 2004			
021437 002	EPLERENONE;INSPIRA	6410054	DEC 08, 2019	U-3	NCE	SEP 27, 2007
		6410524	NOV 05, 2019	U-467		
		4559332	APR 09, 2004			
021437 003	EPLERENONE;INSPIRA	6410054	DEC 08, 2019	U-3	NCE	SEP 27, 2007
		6410524	NOV 05, 2019	U-467		
		4559332	APR 09, 2004			
>ADD> 020738 006	EPROSARTAN MESYLATE;TEVETEN	5185351	FEB 09, 2010	U-3	NCE	DEC 22, 2002
		5656650	AUG 12, 2014	U-3		
021268 001	EPROSARTAN MESYLATE;TEVETEN HCT	5656650	AUG 12, 2014	U-3		
021268 002	EPROSARTAN MESYLATE;TEVETEN HCT	5656650	AUG 12, 2014	U-3		
020718 001	EPTIFIBATIDE;INTEGRILIN	5968902	JUN 02, 2015	U-453		
		5747447	MAY 05, 2015			
020718 002	EPTIFIBATIDE;INTEGRILIN	5968902	JUN 02, 2015	U-453		
		5747447	MAY 05, 2015			
021323 001	ESCITALOPRAM OXALATE;LEXAPRO	RE34712	JUN 08, 2009		NP	AUG 14, 2005
		RE34712*PED	DEC 08, 2009		PED	FEB 14, 2006
					I-366	AUG 29, 2005
					PED	MAR 01, 2006

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021323 002	ESCITALOPRAM OXALATE; LEXAPRO	RE34712 RE34712*PED	JUN 08, 2009 DEC 08, 2009		NP PED I-366 PED	AUG 14, 2005 FEB 14, 2006 AUG 29, 2005 MAR 01, 2006
021323 003	ESCITALOPRAM OXALATE; LEXAPRO	RE34712 RE34712*PED	JUN 08, 2009 DEC 08, 2009		NP PED I-366 PED	AUG 14, 2005 FEB 14, 2006 AUG 29, 2005 MAR 01, 2006
021153 001	ESOMEPRAZOLE MAGNESIUM; NEXIUM	6369085 6428810	MAY 25, 2018 NOV 03, 2019	U-469		
021153 002	ESOMEPRAZOLE MAGNESIUM; NEXIUM	6369085 6428810	MAY 25, 2018 NOV 03, 2019	U-469		
020655 001	ESTRADIOL; ALORA				I-351	APR 05, 2005
020655 002	ESTRADIOL; ALORA				I-351	APR 05, 2005
020655 003	ESTRADIOL; ALORA				I-351	APR 05, 2005
020655 004	ESTRADIOL; ALORA	5122383 5227169 5212199 5164190	MAY 17, 2011 MAY 17, 2011 MAY 17, 2011 DEC 11, 2010		I-351	APR 05, 2005
020538 005	ESTRADIOL; VIVELLE-DOT				I-254	AUG 16, 2003
020538 006	ESTRADIOL; VIVELLE-DOT				I-254	AUG 16, 2003
020538 007	ESTRADIOL; VIVELLE-DOT				I-254	AUG 16, 2003
020538 008	ESTRADIOL; VIVELLE-DOT				I-254	AUG 16, 2003
020992 001	ESTROGENS, CONJUGATED SYNTHETIC A; CENESTIN	5908638	JUL 26, 2015		I-359	JUN 21, 2005
021187 001	ETHINYL ESTRADIOL; NUVARING	5989581	APR 08, 2018			
021241 001	ETHINYL ESTRADIOL; ORTHO TRI-CYCLEN LO	4616006 6214815 4530839 4544554 4628051 RE37721 5846966	SEP 26, 2003 JUN 09, 2019 SEP 26, 2003 SEP 26, 2003 SEP 26, 2003 JUN 16, 2015 SEP 21, 2013	U-112 U-112 U-112 U-112 U-112 U-473 U-474	NP	AUG 22, 2005
>ADD> 021445 001	EZETIMIBE; ZETIA				NCE	OCT 25, 2007
075753 002	FENOFIBRATE; FENOFIBRATE (MICRONI				PC	SEP 15, 2002
075753 003	FENOFIBRATE; FENOFIBRATE (MICRONI				PC	SEP 15, 2002
020625 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	6399632	MAY 11, 2012	U-468		
020872 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	6399632	MAY 11, 2012	U-468		
020872 002	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	6399632	MAY 11, 2012	U-468		
020872 004	FEXOFENADINE HYDROCHLORIDE; ALLEGRA	6399632	MAY 11, 2012	U-468		
020786 001	FEXOFENADINE HYDROCHLORIDE; ALLEGRA-D	6399632	MAY 11, 2012	U-468		
075442 001	FLECAINIDE ACETATE; FLECAINIDE ACETATE				PC	OCT 28, 2002
075442 002	FLECAINIDE ACETATE; FLECAINIDE ACETATE				PC	OCT 28, 2002
075442 003	FLECAINIDE ACETATE; FLECAINIDE ACETATE				PC	OCT 28, 2002
018936 001	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
018936 003	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018936 004	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
018936 006	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
020101 001	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
020974 001	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
020974 002	FLUOXETINE HYDROCHLORIDE; PROZAC				I-362	JUL 29, 2005
018936 007	FLUOXETINE HYDROCHLORIDE; SARAFEM				D-75	JUN 12, 2005
018936 008	FLUOXETINE HYDROCHLORIDE; SARAFEM				D-75	JUN 12, 2005
020121 001	FLUTICASONE PROPIONATE; FLONASE				D-76	MAY 23, 2005
021192 001	FLUVASTATIN SODIUM; LESCOL XL	6242003	APR 13, 2020			
021345 001	FONDAPARINUX SODIUM; ARIXTRA	4818816	AUG 19, 2003			
021344 001	FULVESTRANT; FASLODEX	4659516	OCT 01, 2004		NCE	APR 25, 2007
020235 001	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
		5084479*PED	JUL 02, 2010	U-258		
020235 002	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
		5084479*PED	JUL 02, 2010	U-258		
020235 003	GABAPENTIN; NEURONTIN	5084479	JAN 02, 2010	U-258	I-354	MAY 24, 2005
		5084479*PED	JUL 02, 2010	U-258		
020882 001	GABAPENTIN; NEURONTIN				I-354	MAY 24, 2005
020882 002	GABAPENTIN; NEURONTIN				I-354	MAY 24, 2005
021129 001	GABAPENTIN; NEURONTIN	6054482	APR 25, 2017		I-354	MAY 24, 2005
		6054482*PED	OCT 25, 2017			
>ADD>	020131 001	GADOTERIDOL; PROHANCE	5474756	DEC 12, 2012	U-480	
>ADD>			5846519	DEC 08, 2015		
>ADD>			6143274	DEC 12, 2012	U-480	
021061 001	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015		NCE	DEC 17, 2004
021061 002	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015		NCE	DEC 17, 2004
021062 001	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015			
021062 002	GATIFLOXACIN; TEQUIN	5880283	DEC 05, 2015			
020622 001	GLATIRAMER ACETATE; COPAXONE	6342476	MAY 24, 2014	U-441		
		6362161	MAY 24, 2014	U-441		
021460 001	GLIPIZIDE; METAGLIP				NC	OCT 21, 2005
021460 002	GLIPIZIDE; METAGLIP				NC	OCT 21, 2005
021460 003	GLIPIZIDE; METAGLIP				NC	OCT 21, 2005
021178 001	GLYBURIDE; GLUCOVANCE				I-368	SEP 30, 2005
021178 002	GLYBURIDE; GLUCOVANCE				I-368	SEP 30, 2005
021178 003	GLYBURIDE; GLUCOVANCE				I-368	SEP 30, 2005
020239 001	GRANISETRON HYDROCHLORIDE; KYTRIL				I-369	AUG 16, 2005
020239 002	GRANISETRON HYDROCHLORIDE; KYTRIL				I-369	AUG 16, 2005
020305 002	GRANISETRON HYDROCHLORIDE; KYTRIL	4886808	DEC 20, 2007	U-105		
020125 001	HYDROCHLOROTHIAZIDE; ACCURETIC	4344949	OCT 03, 2002	U-3	NC	DEC 28, 2002
		4743450	FEB 24, 2007		PED	JUN 28, 2003
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
020125 002	HYDROCHLOROTHIAZIDE; ACCURETIC	4743450	FEB 24, 2007			
		4344949	OCT 03, 2002	U-3		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020125 003	HYDROCHLOROTHIAZIDE;ACCURETIC	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
020758 001	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
020758 002	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
020758 003	HYDROCHLOROTHIAZIDE;AVALIDE	5270317	SEP 30, 2011			
020818 001	HYDROCHLOROTHIAZIDE;DIOVAN HCT	6294197	JUN 18, 2017	U-3		
020818 002	HYDROCHLOROTHIAZIDE;DIOVAN HCT	6294197	JUN 18, 2017	U-3		
020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
020729 003	HYDROCHLOROTHIAZIDE;UNIRETIC	4743450	FEB 24, 2007			
020716 001	HYDROCODONE BITARTRATE;VICOPROFEN	6348216	JUN 10, 2017			
021374 001	IBUPROFEN;ADVIL COLD AND SINUS	5071643	DEC 10, 2008			
		5071643*PED	JUN 10, 2009			
		5360615	DEC 10, 2008			
		5360615*PED	JUN 10, 2009			
021373 001	IBUPROFEN;CHILDREN'S ADVIL COL				NP	AUG 01, 2003
					PED	FEB 01, 2004
075874 001	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
075874 002	IFOSFAMIDE;IFOSFAMIDE/MESNA KIT				PC	OCT 05, 2002
020986 001	INSULIN ASPART;NOVOLOG	5618913	APR 08, 2014			
		5866538	JUN 20, 2017			
021172 001	INSULIN ASPART;NOVOLOG MIX 70/30	5547930	SEP 28, 2013			
		5834422	SEP 28, 2013	U-471		
		5948751	JUN 19, 2017			
		5840680	SEP 28, 2013	U-471		
		5618913	APR 08, 2014			
019710 003	IOVERSOL;OPTIRAY 160	4396598	DEC 30, 2002	U-31		
019710 002	IOVERSOL;OPTIRAY 240	4396598	DEC 30, 2002	U-30		
		4396598	DEC 30, 2002	U-29		
019710 004	IOVERSOL;OPTIRAY 300	4396598	DEC 30, 2002	U-29		
		4396598	DEC 30, 2002	U-30		
		4396598	DEC 30, 2002	U-464		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019710 001	IOVERSOL;OPTIRAY 320	4396598	DEC 30, 2002	U-28		
		4396598	DEC 30, 2002	U-29		
019710 005	IOVERSOL;OPTIRAY 350	4396598	DEC 30, 2002	U-463		
		4396598	DEC 30, 2002	U-62		
		4396598	DEC 30, 2002	U-464		
		4396598	DEC 30, 2002	U-465		
>ADD>	020757 001	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011	I-373	SEP 17, 2005
>ADD>	020757 002	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011	I-373	SEP 17, 2005
>ADD>	020757 003	IRBESARTAN;AVAPRO	5270317	SEP 30, 2011	I-373	SEP 17, 2005
	020571 001	IRINOTECAN HYDROCHLORIDE;CAMPTOSAR	6403569	APR 28, 2020	U-449	
	018662 002	ISOTRETINOIN;ACUTANE			M-12	MAY 02, 2005
					PED	NOV 02, 2005
	018662 003	ISOTRETINOIN;ACUTANE			M-12	MAY 02, 2005
					PED	NOV 02, 2005
	018662 004	ISOTRETINOIN;ACUTANE			M-12	MAY 02, 2005
					PED	NOV 02, 2005
	020657 001	ITRACONAZOLE;SPORANOX	6407079	JUN 18, 2019		
	020966 001	ITRACONAZOLE;SPORANOX	6407079	JUN 18, 2019		
	019700 001	KETOROLAC TROMETHAMINE;ACULAR			M-16	FEB 08, 2005
	020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE			M-16	FEB 08, 2005
	020564 001	LAMIVUDINE;EPIVIR			D-2	JUN 24, 2005
	020564 003	LAMIVUDINE;EPIVIR	5047407	NOV 17, 2009	NS	JUN 24, 2005
			5047407*PED	MAY 17, 2010	D-2	JUN 24, 2005
			5905082	MAY 18, 2016		
			5905082*PED	NOV 18, 2016		
			6180639	JAN 30, 2018	U-248	
			6180639*PED	JUL 30, 2018	U-248	
	020596 001	LAMIVUDINE;EPIVIR			D-2	JUN 24, 2005
	020406 001	LANSOPRAZOLE;PREVACID	5013743	FEB 12, 2010	U-452	M-12 JUL 31, 2005
	020406 002	LANSOPRAZOLE;PREVACID	5013743	FEB 12, 2010	U-452	M-12 JUL 31, 2005
	021428 001	LANSOPRAZOLE;PREVACID	4628098	MAY 10, 2009		
			4689333	JUL 29, 2005	U-126	
			5013743	FEB 12, 2010	U-452	
			5026560	JUN 25, 2008		
			5045321	SEP 03, 2008		
			5093132	SEP 03, 2008		
			5433959	SEP 03, 2008		
			5464632	NOV 07, 2012		
			6123962	FEB 13, 2007		
			6328994	MAY 17, 2009		
	021428 002	LANSOPRAZOLE;PREVACID	4628098	MAY 10, 2009		
			4689333	JUL 29, 2005	U-126	
			5013743	FEB 12, 2010	U-452	
			5026560	JUN 25, 2008		
			5045321	SEP 03, 2008		
			5093132	SEP 03, 2008		
			5433959	SEP 03, 2008		
			5464632	NOV 07, 2012		
			6123962	FEB 13, 2007		
			6328994	MAY 17, 2009		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
020597 001	LATANOPROST; XALATAN	6429226	SEP 06, 2009	U-260	
021343 001	LEUPROLIDE ACETATE; ELIGARD	5599552	FEB 04, 2014		
		5733950	OCT 03, 2008		
		5739176	OCT 03, 2008		
		4938763	OCT 03, 2008		
		5278201	JAN 11, 2011		
		5324519	OCT 20, 2011		
021379 001	LEUPROLIDE ACETATE; ELIGARD	5599552	FEB 04, 2014	NP	JUL 24, 2005
		5733950	OCT 03, 2008		
		5739176	OCT 03, 2008		
		4938763	OCT 03, 2008		
		5278201	JAN 11, 2011		
		5324519	OCT 20, 2011		
021088 001	LEUPROLIDE ACETATE; VIADUR	6375978	DEC 17, 2018		
		6395292	JAN 30, 2017		
>ADD>	020837 001	6451289	MAR 21, 2021		
>ADD>	020837 002	6451289	MAR 21, 2021		
>ADD>	020837 003	6451289	MAR 21, 2021	I-347	JAN 30, 2005
		5362755	NOV 08, 2011	U-332	
		5547994	AUG 20, 2013	U-332	
		5760090	JAN 05, 2010	U-332	
		5844002	JAN 05, 2010	U-332	
		6083993	JAN 05, 2010	U-332	
020182 001	LEVOCARNITINE; CARNITOR	6335369	JAN 18, 2021	U-433	
		6429230	JAN 18, 2021	U-433	
020634 001	LEVOFLOXACIN; LEVAQUIN			I-357	APR 08, 2003
>ADD>				I-372	OCT 30, 2005
020634 002	LEVOFLOXACIN; LEVAQUIN			I-357	APR 08, 2003
>ADD>				I-372	OCT 30, 2005
020634 003	LEVOFLOXACIN; LEVAQUIN			I-305	FEB 02, 2003
>ADD>				I-357	APR 08, 2003
020635 001	LEVOFLOXACIN; LEVAQUIN			I-372	OCT 30, 2005
>ADD>				I-357	APR 08, 2003
020635 002	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE			I-372	OCT 30, 2005
>ADD>				I-357	APR 08, 2003
>ADD>				I-372	OCT 30, 2005
020635 003	LEVOFLOXACIN; LEVAQUIN IN DEXTROSE			I-357	APR 08, 2003
>ADD>				I-372	OCT 30, 2005
021342 001	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020		
021342 002	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020		
021342 003	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020		
021342 004	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020		
021342 005	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020		
021342 006	LEVOTHYROXINE SODIUM; LEVO-T	6399101	MAR 30, 2020		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021342 007	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 008	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 009	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 010	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021342 011	LEVOTHYROXINE SODIUM;LEVO-T	6399101	MAR 30, 2020			
021226 001	LOPINAVIR;KALETRA	6458818	NOV 07, 2017			
>ADD> 020470 001	LORATADINE;CLARITIN-D 24 HOUR	5314697	OCT 23, 2012			
020386 001	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
020386 002	LOSARTAN POTASSIUM;COZAAR	5153197	OCT 06, 2009	U-3		
		5138069	AUG 11, 2009			
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
		5153197	OCT 06, 2009	U-3		
		5608075	MAR 04, 2014			
		5138069*PED	FEB 11, 2010			
		5153197*PED	APR 06, 2010	U-3		
		5608075*PED	SEP 04, 2014			
021249 001	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447		
		6129930	SEP 20, 2013	U-448		
		6406715	OCT 31, 2017	U-450		
021249 002	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447		
		6129930	SEP 20, 2013	U-448		
		6406715	OCT 31, 2017	U-450		
021249 003	LOVASTATIN;ADVICOR	6080428	MAY 27, 2017	U-447		
		6129930	SEP 20, 2013	U-448		
		6406715	OCT 31, 2017	U-450		
021316 001	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JAN 30, 2005
		6080778	MAR 23, 2018	U-456		
021316 002	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JAN 30, 2005
		6080778	MAR 23, 2018	U-456		
021316 003	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JAN 30, 2005
		6080778	MAR 23, 2018	U-456		
021316 004	LOVASTATIN;ALTOCOR	5916595	DEC 12, 2017		NDF	JAN 30, 2005
		6080778	MAR 23, 2018	U-456		
019643 002	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
					I-350	FEB 14, 2005

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019643 003	LOVASTATIN;MEVACOR				PED	AUG 14, 2005
019643 004	LOVASTATIN;MEVACOR				I-350	FEB 14, 2005
020652 001	MANGAFODIPIR TRISODIUM;TESLASCAN	4933456	NOV 27, 2011		PED	AUG 14, 2005
076175 001	MEFLOQUINE HYDROCHLORIDE;MEFLOQUINE HCL				I-350	FEB 14, 2005
020938 002	MELOXICAM;MOBIC				PC	NOV 03, 2002
020922 001	MEQUINOL;SOLAGE	6353029	AUG 24, 2020		NCE	APR 13, 2005
020855 001	MESNA;MESNEX				NDF	MAR 21, 2005
013217 001	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U-189		
013217 003	METAXALONE;SKELAXIN	6407128	DEC 03, 2021	U-189		
020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				PED	JUN 15, 2004
					I-320	DEC 15, 2003
					W	DEC 15, 2003
					W	JUN 15, 2004
021202 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE XR	6475521	MAR 19, 2018			
021121 004	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4519801	JUL 12, 2002		NP	AUG 01, 2003
		4612008	SEP 16, 2003			
		4783337	SEP 16, 2003	U-372		
		5082668	SEP 16, 2003			
021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD	6344215	OCT 27, 2020			
021284 001	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	MAY 01, 2019	U-472		
021284 002	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	MAY 01, 2019	U-472		
021284 003	METHYLPHENIDATE HYDROCHLORIDE;RITALIN LA	5837284	MAY 15, 2016		NP	JUN 07, 2005
		6228398	NOV 01, 2019	U-472		
020415 001	MIRTAZAPINE;REMERON				M-18	APR 09, 2005

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES
020415 002	MIRTAZAPINE; REMERON			M-18	APR 09, 2005
020415 003	MIRTAZAPINE; REMERON			M-18	APR 09, 2005
>ADD> 021208 001	MIRTAZAPINE; REMERON SOLTAB			M-18	APR 09, 2005
>ADD> 021208 002	MIRTAZAPINE; REMERON SOLTAB			M-18	APR 09, 2005
>ADD> 021208 003	MIRTAZAPINE; REMERON SOLTAB			M-18	APR 09, 2005
019297 001	MITOXANTRONE HYDROCHLORIDE; NOVANTRONE			ODE	OCT 13, 2007
020762 001	MOMETASONE FUROATE MONOHYDRATE; NASONEX			I-360	JUL 17, 2005
				PED	JAN 17, 2006
021409 001	MONTELUKAST SODIUM; SINGULAIR	5565473	FEB 03, 2012	NDF	JUL 26, 2005
		5565473*PED	AUG 03, 2012	PED	JAN 26, 2006
				NCE	FEB 20, 2003
				PED	AUG 20, 2003
021260 001	MORPHINE SULFATE; AVINZA	6066339	NOV 25, 2017	NP	MAR 20, 2005
021260 002	MORPHINE SULFATE; AVINZA	6066339	NOV 25, 2017	NP	MAR 20, 2005
021260 003	MORPHINE SULFATE; AVINZA	6066339	NOV 25, 2017	NP	MAR 20, 2005
021260 004	MORPHINE SULFATE; AVINZA	6066339	NOV 25, 2017	NP	MAR 20, 2005
019583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		
		4420639*PED	JUN 13, 2003		
019583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		
		4420639*PED	JUN 13, 2003		
020763 001	NARATRIPTAN HYDROCHLORIDE; AMERGE	4997841	JUL 07, 2010	U-232	
020763 002	NARATRIPTAN HYDROCHLORIDE; AMERGE	4997841	JUL 07, 2010	U-232	
020152 001	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		
		5256664	APR 28, 2012		
		4338317*PED	SEP 16, 2003		
		5256664*PED	OCT 28, 2012		
020152 002	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		
		5256664	APR 28, 2012		
		4338317*PED	SEP 16, 2003		
		5256664*PED	OCT 28, 2012		
020152 003	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		
		5256664	APR 28, 2012		
		4338317*PED	SEP 16, 2003		
		5256664*PED	OCT 28, 2012		
020152 004	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		
		5256664	APR 28, 2012		
		4338317*PED	SEP 16, 2003		
		5256664*PED	OCT 28, 2012		
020152 005	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		
		5256664	APR 28, 2012		
		4338317*PED	SEP 16, 2003		
		5256664*PED	OCT 28, 2012		
020152 006	NEFAZODONE HYDROCHLORIDE; SERZONE	4338317	MAR 16, 2003		
		5256664	APR 28, 2012		
		4338317*PED	SEP 16, 2003		
		5256664*PED	OCT 28, 2012		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020778 001	NELFINAVIR MESYLATE;VIRACEPT	6162812	OCT 07, 2013	U-248		
020779 001	NELFINAVIR MESYLATE;VIRACEPT	6162812	OCT 07, 2013	U-248		
020381 001	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
020381 002	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
020381 003	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
020381 004	NIACIN;NIASPAN	6406715	OCT 31, 2017	U-450		
020381 005	NIACIN;NIASPAN TITRATION ST	6406715	OCT 31, 2017	U-450		
		6129930	SEP 20, 2013	U-354		
021330 001	NICOTINE POLACRILEX;COMMIT				NDF	OCT 31, 2005
021330 002	NICOTINE POLACRILEX;COMMIT				NDF	OCT 31, 2005
020076 004	NICOTINE;HABITROL				D-71	NOV 12, 2002
020076 005	NICOTINE;HABITROL				D-71	NOV 12, 2002
020076 006	NICOTINE;HABITROL				D-71	NOV 12, 2002
>ADD>	021498 001	NITAZOXANIDE;ALINIA			NCE	NOV 22, 2007
>ADD>					ODE	NOV 22, 2009
020555 001	NIZATIDINE;AXID AR	4375547	APR 12, 2002			
021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	6395292	JAN 30, 2017			
021286 001	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
021286 003	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
021286 004	OLMESARTAN MEDOXOMIL;BENICAR				NCE	APR 25, 2007
019810 001	OMEPRAZOLE;PRILOSEC	6166213*PED	APR 09, 2019		M-19	JUL 12, 2005
					PED	JAN 12, 2006
019810 002	OMEPRAZOLE;PRILOSEC	6166213*PED	APR 09, 2019		M-19	JUL 12, 2005
					PED	JAN 12, 2006
019810 003	OMEPRAZOLE;PRILOSEC	6166213	OCT 09, 2018		M-19	JUL 12, 2005
		6166213*PED	APR 09, 2019		PED	JAN 12, 2006
020766 001	ORLISTAT;XENICAL	4598089	JUN 18, 2009			
021492 001	OXALIPLATIN;ELOXATIN	5420319	APR 07, 2013		NCE	AUG 09, 2007
		5338874	APR 07, 2013			
		5290961	JAN 12, 2013			
021492 002	OXALIPLATIN;ELOXATIN	5420319	APR 07, 2013		NCE	AUG 09, 2007
		5338874	APR 07, 2013			
		5290961	JAN 12, 2013			
021285 001	OXCARBAZEPINE;TRILEPTAL				NCE	JAN 14, 2005
020553 001	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
020553 002	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020553 003	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
020553 004	OXYCODONE HYDROCHLORIDE; OXYCONTIN	5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
		4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
020553 005	OXYCODONE HYDROCHLORIDE; OXYCONTIN	4970075	AUG 29, 2006			
		5266331	OCT 26, 2007			
		5549912	OCT 26, 2007			
		5508042	APR 16, 2013	U-443		
		5656295	OCT 26, 2007	U-443		
>ADD> 020987 001	PANTOPRAZOLE SODIUM; PROTONIX	5997903	DEC 07, 2016		I-356	APR 19, 2005
>ADD> 020987 002	PANTOPRAZOLE SODIUM; PROTONIX	5997903	DEC 07, 2016		I-356	APR 19, 2005
		4758579	JUL 19, 2005		I-330	JUN 12, 2004
					NCE	FEB 02, 2005
020031 001	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			
020031 002	PAROXETINE HYDROCHLORIDE; PAXIL	4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		5789449*	PED JUL 06, 2009	U-285		
		5872132*	PED NOV 19, 2015			
		5900423*	PED NOV 19, 2015			
		6063927*	PED OCT 23, 2019			
		6080759*	PED NOV 19, 2015			
		6113944*	PED JUN 14, 2015			
		6121291*	PED SEP 17, 2017	U-286		
		6121291*	PED SEP 17, 2017	U-431		
		6133289*	PED NOV 19, 2015	U-358		
		6172233*	PED JUL 15, 2018			
020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*	PED JUN 29, 2007	U-12		
		5789449*	PED JUL 06, 2009	U-285		
		5872132*	PED NOV 19, 2015			
		5900423*	PED NOV 19, 2015			
		6063927*	PED OCT 23, 2019			
		6080759*	PED NOV 19, 2015			
		6113944*	PED JUN 14, 2015			
		6121291*	PED SEP 17, 2017	U-286		
		6121291*	PED SEP 17, 2017	U-431		
		6133289*	PED NOV 19, 2015	U-358		
		6172233*	PED JUL 15, 2018			
020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6133289	MAY 15, 2015	U-358		
		6121291	MAR 17, 2017	U-286		
		6121291	MAR 17, 2017	U-431		
		6172233	JAN 15, 2018			
		4721723*	PED JUN 29, 2007	U-12		
		5789449*	PED JUL 06, 2009	U-285		
		5872132*	PED NOV 19, 2015			
		5900423*	PED NOV 19, 2015			
		6063927*	PED OCT 23, 2019			
		6080759*	PED NOV 19, 2015			
		6113944*	PED JUN 14, 2015			
		6121291*	PED SEP 17, 2017	U-286		
		6121291*	PED SEP 17, 2017	U-431		
		6133289*	PED NOV 19, 2015	U-358		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020031 005	PAROXETINE HYDROCHLORIDE;PAXIL	6172233*PED	JUL 15, 2018			
		4721723	DEC 29, 2006	U-12	I-261	MAY 17, 2002
		5872132	MAY 19, 2015		I-326	APR 13, 2004
		5900423	MAY 19, 2015		I-345	DEC 14, 2004
		5789449	JAN 06, 2009	U-285	PED	OCT 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	NOV 17, 2002
		6113944	DEC 14, 2014			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 15, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6113944*PED	JUN 14, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
6172233*PED	JUL 15, 2018					
020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-261	MAY 17, 2002
		5811436	SEP 22, 2015		PED	NOV 17, 2002
		5872132	MAY 19, 2015		I-345	DEC 14, 2004
		5900423	MAY 19, 2015		I-326	APR 13, 2004
		5789449	JAN 06, 2009	U-285	PED	JUN 14, 2005
		6063927	APR 23, 2019		PED	OCT 13, 2004
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007			
		5789449*PED	JUL 06, 2009	U-285		
		5811436*PED	MAR 22, 2016			
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		6172233*PED	JUL 15, 2018			

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			
		5900423*PED	NOV 19, 2015			
		6063927*PED	OCT 23, 2019			
		6080759*PED	NOV 19, 2015			
		6121291*PED	SEP 17, 2017	U-286		
		6121291*PED	SEP 17, 2017	U-431		
		6133289*PED	NOV 19, 2015	U-358		
		020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015	
5900423	MAY 19, 2015				PED	NOV 17, 2002
5789449	JAN 06, 2009			U-285	I-345	DEC 14, 2004
4721723	DEC 29, 2006			U-12	I-326	APR 13, 2004
6063927	APR 23, 2019				PED	JUN 14, 2005
6080759	MAY 19, 2015				PED	OCT 13, 2004
6121291	MAR 17, 2017			U-286		
6133289	MAY 19, 2015			U-358		
6172233	JAN 15, 2018					
6121291	MAR 17, 2017			U-431		
4721723*PED	JUN 29, 2007			U-12		
5789449*PED	JUL 06, 2009			U-285		
5872132*PED	NOV 19, 2015					
5900423*PED	NOV 19, 2015					
6063927*PED	OCT 23, 2019					
6080759*PED	NOV 19, 2015					
6121291*PED	SEP 17, 2017			U-286		
6121291*PED	SEP 17, 2017			U-431		
6133289*PED	NOV 19, 2015			U-358		
020885 003	PAROXETINE HYDROCHLORIDE;PAXIL			5872132	MAY 19, 2015	
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6063927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*PED	JUN 29, 2007	U-12		
		5789449*PED	JUL 06, 2009	U-285		
		5872132*PED	NOV 19, 2015			

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		5900423*	PED NOV 19, 2015			
		6063927*	PED OCT 23, 2019			
		6080759*	PED NOV 19, 2015			
		6121291*	PED SEP 17, 2017	U-286		
		6121291*	PED SEP 17, 2017	U-431		
		6133289*	PED NOV 19, 2015	U-358		
		6172233*	PED JUL 15, 2018			
020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	5872132	MAY 19, 2015		I-261	MAY 17, 2002
		5900423	MAY 19, 2015		PED	NOV 17, 2002
		5789449	JAN 06, 2009	U-285	I-345	DEC 14, 2004
		4721723	DEC 29, 2006	U-12	I-326	APR 13, 2004
		6062927	APR 23, 2019		PED	JUN 14, 2005
		6080759	MAY 19, 2015		PED	OCT 13, 2004
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-358		
		6172233	JAN 15, 2018			
		6121291	MAR 17, 2017	U-431		
		4721723*	PED JUN 29, 2007	U-12		
		5789449*	PED JUL 06, 2009	U-285		
		5872132*	PED NOV 19, 2015			
		5900423*	PED NOV 19, 2015			
		6063927*	PED OCT 23, 2019			
		6080759*	PED NOV 19, 2015			
		6121291*	PED SEP 17, 2017	U-286		
		6121291*	PED SEP 17, 2017	U-431		
		6133289*	PED NOV 19, 2015	U-358		
		6172233*	PED JUL 15, 2018			
020936 001	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005
		4839177	JUN 13, 2006		PED	AUG 12, 2005
		5422123	JUN 06, 2012			
		4721723	DEC 29, 2006			
		5900423	MAY 19, 2015			
		5789449	JAN 06, 2009	U-286		
		6063927	APR 23, 2019			
		6080759	MAY 19, 2015			
		6121291	MAR 17, 2017	U-286		
		6133289	MAY 19, 2015	U-286		
		6172233	JAN 15, 2018			
		4721723*	PED JUN 29, 2007			
		4839177*	PED DEC 13, 2006			
		5422123*	PED DEC 06, 2012			
		5789449*	PED JUL 06, 2009	U-286		
		5872132*	PED NOV 19, 2015			
		5900423*	PED NOV 19, 2015			
		6063927*	PED OCT 23, 2019			
		6080759*	PED NOV 19, 2015			
		6121291*	PED SEP 17, 2017	U-286		
		6133289*	PED NOV 19, 2015	U-286		
		6172233*	PED JUL 15, 2018			

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES	
020936 002	PAROXETINE HYDROCHLORIDE;PAXIL CR	5872132	MAY 19, 2015		I-358	FEB 12, 2005	
		4839177	JUN 13, 2006		PED	AUG 12, 2005	
		5422123	JUN 06, 2012				
		4721723	DEC 29, 2006				
		5900423	MAY 19, 2015				
		5789449	JAN 06, 2009	U-286			
		6063927	APR 23, 2019				
		6080759	MAY 19, 2015				
		6121291	MAR 17, 2017	U-286			
		6133289	MAY 19, 2015	U-286			
		6172233	JAN 15, 2018				
		4721723*PED	JUN 29, 2007				
		4839177*PED	DEC 13, 2006				
		5422123*PED	DEC 06, 2012				
		5789449*PED	JUL 06, 2009	U-286			
		5872132*PED	NOV 19, 2015				
		5900423*PED	NOV 19, 2015				
		6063927*PED	OCT 23, 2019				
		6080759*PED	NOV 19, 2015				
		6121291*PED	SEP 17, 2017	U-286			
6133289*PED	NOV 19, 2015	U-286					
6172233*PED	JUL 15, 2018						
020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006		I-358	FEB 12, 2005	
		4839177	JUN 13, 2006		PED	AUG 12, 2005	
		5422123	JUN 06, 2012				
		5789449	JAN 06, 2009	U-286			
		5872132	MAY 19, 2015				
		5900423	MAY 19, 2015				
		6063927	APR 23, 2019				
		6080759	MAY 19, 2015				
		6121291	MAR 17, 2017	U-286			
		6133289	MAY 19, 2015	U-286			
		6172233	JAN 15, 2018				
		4721723*PED	JUN 29, 2007				
		4839177*PED	DEC 13, 2006				
		5422123*PED	DEC 06, 2012				
		5789449*PED	JUL 06, 2009	U-286			
		5872132*PED	NOV 19, 2015				
		5900423*PED	NOV 19, 2015				
		6063927*PED	OCT 23, 2019				
		6080759*PED	NOV 19, 2015				
		6121291*PED	SEP 17, 2017	U-286			
6133289*PED	NOV 19, 2015	U-286					
6172233*PED	JUL 15, 2018						

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020629 001	PENCICLOVIR SODIUM;DENA VIR	5075445	SEP 24, 2010			
021302 001	PIMECROLIMUS;ELIDEL	6352998	OCT 26, 2015			
		6352998*PED	APR 26, 2016			
		6423722	JUN 26, 2018			
		6423722*PED	DEC 26, 2018			
021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6303640	AUG 09, 2016	U-425		
019898 002	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		I-281	JUN 09, 2003
		5180589	JUL 09, 2008		I-304	JAN 18, 2003
		5030447	JUL 09, 2008		I-287	FEB 10, 2003
		5622985	APR 22, 2014	U-335	I-286	JAN 18, 2003
		4346227*PED	APR 20, 2006		D-51	JAN 18, 2003
		5180589*PED	JAN 09, 2009		D-70	DEC 18, 2004
		5622985*PED	OCT 22, 2014	U-335	PED	DEC 09, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006
					I-281	JUN 09, 2003
					I-304	JAN 18, 2003
					I-287	FEB 10, 2003
				U-335	I-286	JAN 18, 2003
					D-51	JAN 18, 2003
					D-70	DEC 18, 2004
				U-335	PED	DEC 09, 2003
					PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006
					I-281	JUN 09, 2003
					I-304	JAN 18, 2003
					I-287	FEB 10, 2003
				U-335	I-286	JAN 18, 2003
					D-51	JAN 18, 2003
					D-70	DEC 18, 2004
				U-335	PED	DEC 09, 2003
					PED	JUL 18, 2003
					PED	JUL 18, 2003
					PED	AUG 10, 2003
					PED	JUN 18, 2005
					PED	JUL 18, 2003
					PED	JUN 18, 2005
					I-370	OCT 29, 2005
					PED	APR 29, 2006

>ADD>

>ADD>

>ADD>

>ADD>

>ADD>

>ADD>

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019898 008	PRAVASTATIN SODIUM;PRAVACHOL	4346227	OCT 20, 2005		NS	DEC 18, 2004
		5030447	JUL 09, 2008		D-70	DEC 18, 2004
		5180589	JUL 09, 2008		PED	JUN 18, 2005
		5622985	APR 22, 2014	U-335	PED	JUN 18, 2005
		4346227*PED	APR 20, 2006		I-281	JUN 09, 2003
		5180589*PED	JAN 09, 2009		PED	DEC 09, 2003
		5622985*PED	OCT 22, 2014	U-335	D-51	JAN 18, 2003
		5030447*PED	JAN 09, 2009		PED	JUL 18, 2003
					I-286	JAN 18, 2003
					PED	JUL 18, 2003
					I-287	FEB 10, 2003
					PED	AUG 10, 2003
					I-304	JAN 18, 2003
			PED	JUL 18, 2003		
			I-370	OCT 29, 2005		
			PED	APR 29, 2006		
>ADD> >ADD>						
019885 001	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
		4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
019885 002	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
		4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
019885 003	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
		4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
019885 004	QUINAPRIL HYDROCHLORIDE;ACCUPRIL	5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		
		4344949	OCT 03, 2002	U-3		
		4743450	FEB 24, 2007			
		5684016	NOV 04, 2014	U-210		
		5747504	APR 10, 2005	U-210		
		4344949*PED	APR 03, 2003	U-3		
		4743450*PED	AUG 24, 2007			
		5684016*PED	MAY 04, 2015	U-210		
		5747504*PED	OCT 10, 2005	U-210		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020973 001	RABEPRAZOLE SODIUM;ACIPHEX	5035899	APR 04, 2009	U-385	NCE	AUG 19, 2004
>ADD>	020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385	I-346 FEB 12, 2005
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA			I-371	NOV 08, 2005
>ADD>	020741 001	REPAGLINIDE;PRANDIN	4418068	APR 03, 2003		
>ADD>			6458811	MAR 10, 2017		
>ADD>			5312924	SEP 05, 2006	I-367	OCT 21, 2005
>ADD>			6143769	SEP 05, 2006		
>ADD>			RE37035	MAR 14, 2009		
>ADD>	020741 002	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006	U-214	I-367 OCT 21, 2005
>ADD>			6143769	SEP 05, 2006		
>ADD>			RE37035	MAR 14, 2009		
>ADD>	020741 003	REPAGLINIDE;PRANDIN	5312924	SEP 05, 2006	U-214	I-367 OCT 21, 2005
>ADD>			6143769	SEP 05, 2006		
>ADD>			RE37035	MAR 14, 2009		
>ADD>	020903 001	RIBAVIRIN;REBETOL	6472373	SEP 21, 2017	U-479	
>ADD>			6472373*PED	MAR 21, 2018	U-479	
			6177074	NOV 01, 2016	U-454	
			6177074*PED	MAY 01, 2017	U-454	
			6461605	NOV 01, 2016	U-478	
			6461605*PED	MAY 01, 2017	U-478	
020599 001	RILUZOLE;RILUTEK	5527814	JUN 18, 2013			
020835 003	RISEDRONATE SODIUM;ACTONEL	5994329	JUL 17, 2018	U-353	NCE	MAR 27, 2003
		6015801	JUL 17, 2018	U-353	I-292	APR 14, 2003
					I-291	APR 14, 2003
					D-73	MAY 17, 2005
					D-74	MAY 17, 2005
					M-15	MAR 03, 2005
020272 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 002	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 003	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 004	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 005	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 007	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020272 008	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020588 001	RISPERIDONE;RISPERDAL				M-15	MAR 03, 2005
020864 001	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
020864 002	RIZATRIPTAN BENZOATE;MAXALT	5298520	JUN 29, 2012	U-240		
020865 001	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
020865 002	RIZATRIPTAN BENZOATE;MAXALT-MLT	5298520	JUN 29, 2012	U-240		
021042 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
021042 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
021042 003	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017			

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021052 001	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
021052 002	ROFECOXIB;VIOXX	5691374	MAY 18, 2015		I-353	APR 11, 2005
		6063811	MAY 06, 2017	U-266		
020658 001	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 002	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 003	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 004	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 005	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 006	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020658 007	ROPINIROLE HYDROCHLORIDE;REQUIP	4452808	DEC 07, 2007			
020692 001	SALMETEROL XINAFOATE;SEREVENT				I-348	MAR 22, 2005
020828 001	SAQUINAVIR;FORTOVASE	6352717	NOV 16, 2019			
		6008228	JUN 06, 2015			
021209 001	SECRETIN;SECREFLO				NP ODE	APR 04, 2005 APR 04, 2009
019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 003	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 004	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT	4536518	DEC 30, 2005	U-12	I-355	MAY 16, 2005
		4536518*PED	JUN 30, 2006	U-12		
		5248699	AUG 13, 2012			
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020990 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	5248699	AUG 13, 2012		I-355	MAY 16, 2005
		5248699*PED	FEB 13, 2013			
		5744501	JAN 06, 2009	U-461		
		5789449	JAN 06, 2009	U-460		
020478 001	SEVOFLURANE; ULTANE	6444859	JAN 27, 2017		M-17	MAR 30, 2004
		6444859*PED	JUL 27, 2017		PED	SEP 30, 2004
020632 001	SIBUTRAMINE HYDROCHLORIDE; MERIDIA	4746680	JUN 11, 2007			
		5436272	JUL 25, 2012	U-439		
020632 002	SIBUTRAMINE HYDROCHLORIDE; MERIDIA	4746680	JUN 11, 2007			
		5436272	JUL 25, 2012	U-439		
020632 003	SIBUTRAMINE HYDROCHLORIDE; MERIDIA	4746680	JUN 11, 2007			
		5436272	JUL 25, 2012	U-439		
020895 001	SILDENAFIL CITRATE; VIAGRA	5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U-155		
020895 002	SILDENAFIL CITRATE; VIAGRA	5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U-155		
020895 003	SILDENAFIL CITRATE; VIAGRA	5250534	MAR 27, 2012			
		6469012	OCT 22, 2019	U-155		
019766 001	SIMVASTATIN; ZOCOR				I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 002	SIMVASTATIN; ZOCOR				I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 003	SIMVASTATIN; ZOCOR				I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 004	SIMVASTATIN; ZOCOR				I-350	OCT 18, 2005
					PED	APR 18, 2006
019766 005	SIMVASTATIN; ZOCOR				I-350	OCT 18, 2005
					PED	APR 18, 2006
>ADD>	021110 001	SIROLIMUS; RAPAMUNE	5100899	JUN 06, 2009	U-290	
>ADD>			5212155	MAY 18, 2010	U-291	
>ADD>			5308847	MAY 03, 2011	U-292	
>ADD>			5403833	APR 04, 2012	U-293	
>ADD>			5989591	MAR 11, 2018		
021196 001	SODIUM OXYBATE; XYREM				ODE NCE	JUL 17, 2009 JUL 17, 2007
020572 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2004	U-136		
020573 001	SODIUM PHENYLBUTYRATE; BUPHENYL	4457942	AUG 20, 2004	U-136		
021075 001	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12, 2012			
021075 002	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12, 2012			
021075 003	SOMATROPIN RECOMBINANT; NUTROPIN DEPOT	5912015	MAR 12, 2012			
020604 004	SOMATROPIN RECOMBINANT; SEROSTIM				ODE	AUG 23, 2003
020677 001	SPARFLOXACIN; ZAGAM	4795751	FEB 04, 2010	U-160		
020132 001	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02, 2012	U-444		
020132 002	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02, 2012	U-444		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020132 003	SUMATRIPTAN SUCCINATE; IMITREX	6368627	MAR 02, 2012	U-444		
017970 001	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002		M-20	AUG 30, 2005
		4536516*PED	FEB 20, 2003		PED	MAR 01, 2006
017970 002	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002			
		4536516*PED	FEB 20, 2003			
>ADD>	021184 003	TAZAROTENE; AVAGE	5089509	JUN 13, 2011	U-481 NP	SEP 30, 2005
>ADD>	020600 001	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U-193	
>ADD>			5089509	JUN 13, 2011	U-481	
>ADD>	020600 002	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U-193	
>ADD>			5089509	JUN 13, 2011	U-481	
>ADD>	021184 001	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U-481	
>ADD>	021184 002	TAZAROTENE; TAZORAC	5089509	JUN 13, 2011	U-481	
	019785 001	TECHNETIUM TC-99M SESTAMIBI KIT; CARDIOLITE	4452774	DEC 21, 2004		
	019785 003	TECHNETIUM TC-99M SESTAMIBI KIT; MIRALUMA	4452774	DEC 21, 2004		
	021200 001	TEGASEROD MALEATE; ZELNORM	5510353	APR 26, 2013	U-466 NCE	JUL 24, 2007
	021200 002	TEGASEROD MALEATE; ZELNORM	5510353	APR 26, 2013	U-466 NCE	JUL 24, 2007
	021029 001	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010		
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
	021029 002	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010	NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
	021029 003	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010	NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
	021029 004	TEMOZOLOMIDE; TEMODAR	5260291	NOV 09, 2010	NCE	AUG 11, 2004
		5260291*PED	MAY 09, 2011		ODE	AUG 11, 2006
					PED	FEB 11, 2005
					PED	FEB 11, 2007
	020846 001	TERBINAFINE; LAMISIL	4755534	DEC 30, 2006	U-445	
		4680291	JUL 14, 2004	U-445		
>ADD>	021318 001	TERIPARATIDE ACETATE; FORTERO			NP	NOV 26, 2005
	020791 001	TESTOSTERONE; TESTODERM TTS	6348210	NOV 10, 2019	U-440	
	020785 001	THALIDOMIDE; THALOMID	6315720	OCT 23, 2020	U-442	
>ADD>	020646 001	TIAGABINE HYDROCHLORIDE; GABITRIL	5010090	SEP 30, 2011		
>ADD>			5958951	JUN 10, 2017		
>ADD>			5866590	APR 29, 2016		
>ADD>	020646 002	TIAGABINE HYDROCHLORIDE; GABITRIL	5010090	SEP 30, 2011		
>ADD>			5958951	JUN 10, 2017		
>ADD>			5866590	APR 29, 2016		
>ADD>	020646 003	TIAGABINE HYDROCHLORIDE; GABITRIL	5010090	SEP 30, 2011		
>ADD>			5958951	JUN 10, 2017		
>ADD>			5866590	APR 29, 2016		

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL USE EXPIRES	EXCLUS CODE	EXCLUS EXPIRES	
>ADD> >ADD> >ADD> >ADD> >ADD>	020646 004 020646 005	TIAGABINE HYDROCHLORIDE; GABITRIL TIAGABINE HYDROCHLORIDE; GABITRIL	5010090 5958951 5866590 5010090 5958951 5866590	SEP 30, 2011 JUN 10, 2017 APR 29, 2016 SEP 30, 2011 JUN 10, 2017 APR 29, 2016		
	021447 001 021447 002 021447 003 020697 001 020697 002 021228 001 021228 002 020671 001	TIZANIDINE HYDROCHLORIDE; ZANAFLEX TIZANIDINE HYDROCHLORIDE; ZANAFLEX TIZANIDINE HYDROCHLORIDE; ZANAFLEX TOLCAPONE; TASMAR TOLCAPONE; TASMAR TOLTERODINE TARTRATE; DETROL LA TOLTERODINE TARTRATE; DETROL LA TOPOTECAN HYDROCHLORIDE; Hycamtin	6455557 6455557 6455557 5236952 5236952 5559269 5559269 5004758 5004758*PED	NOV 28, 2021 NOV 28, 2021 NOV 28, 2021 JAN 29, 2012 JAN 29, 2012 NOV 05, 2013 NOV 05, 2013 MAY 28, 2010 NOV 28, 2010		
	076110 001 076110 002 076110 003 076110 004 021272 001 021272 002 021272 003 021272 004 020475 002 021289 001 020550 001	TORSEMIDE; TORSEMIDE TORSEMIDE; TORSEMIDE TORSEMIDE; TORSEMIDE TORSEMIDE; TORSEMIDE TREPROSTINIL SODIUM; REMODULIN TREPROSTINIL SODIUM; REMODULIN TREPROSTINIL SODIUM; REMODULIN TREPROSTINIL SODIUM; REMODULIN TRETINOIN; RETIN-A MICRO UROFOLLITROPIN; BRAVELLE VALACYCLOVIR HYDROCHLORIDE; VALTREX			PC PC PC PC U-455 NCE ODE U-455 NCE ODE U-455 NCE ODE U-455 NCE ODE U-134 NS U-134 NP	FEB 17, 2003 DEC 10, 2002 DEC 07, 2002 DEC 10, 2002 MAY 21, 2007 MAY 21, 2009 MAY 21, 2007 MAY 21, 2009 MAY 21, 2007 MAY 21, 2009 MAY 21, 2009 MAY 10, 2005 MAY 06, 2005
	020550 002	VALACYCLOVIR HYDROCHLORIDE; VALTREX	4957924 5879706 6107302 4957924 5879706 6107302	JUN 23, 2009 JAN 19, 2016 JAN 19, 2016 JUN 23, 2009 JAN 19, 2016 JAN 19, 2016		
	021341 002 021341 003 020593 001 020665 001 020665 002 021283 001 021283 002 021283 003	VALDECOXIB; BEXTRA VALDECOXIB; BEXTRA VALPROATE SODIUM; DEPACON VALSARTAN; DIOVAN VALSARTAN; DIOVAN VALSARTAN; DIOVAN VALSARTAN; DIOVAN VALSARTAN; DIOVAN	5633272 5633272 5633272 6294197 6294197 6294197	FEB 13, 2015 FEB 13, 2015 FEB 13, 2015 JUN 18, 2017 JUN 18, 2017 JUN 18, 2017	U-462 U-462 D-72 I-365 I-365 U-3 U-3 U-3	JAN 24, 2005 AUG 14, 2005 AUG 14, 2005 AUG 14, 2005 AUG 14, 2005 AUG 14, 2005

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021283 004	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		I-365	AUG 14, 2005
		6294197	JUN 18, 2017	U-3		
>ADD>	020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007	I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	SEP 02, 2004
>ADD>	020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007	I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	SEP 02, 2004
>ADD>	020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007	I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	SEP 02, 2004
>ADD>	020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007	I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	SEP 02, 2004
>ADD>	020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007	I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	SEP 02, 2004
>ADD>	020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	4535186	DEC 13, 2007	I-325	MAY 02, 2004
>ADD>		4535186*PED	JUN 13, 2008		PED	SEP 02, 2004
>ADD>	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007	I-325	MAY 02, 2004
>ADD>		6274171	MAR 20, 2017		PED	SEP 02, 2004
>ADD>		5916923	JUN 28, 2013	U-398		
>ADD>		6403120	MAR 20, 2017	U-451		
>ADD>		6419958	MAR 20, 2017	U-459		
>ADD>		6444708	JUN 28, 2013			
>ADD>		4535186*PED	JUN 13, 2008			
>ADD>		5916923*PED	DEC 28, 2013	U-398		
>ADD>		6274171*PED	SEP 20, 2017			
>ADD>		6403120*PED	SEP 20, 2017	U-451		
>ADD>		6419958*PED	SEP 20, 2013	U-459		
>ADD>		6444708*PED	DEC 28, 2013			
>ADD>	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007	I-325	MAY 02, 2004
>ADD>		6274171	MAR 20, 2017		PED	SEP 02, 2004
>ADD>		5916923	JUN 28, 2013	U-398		
>ADD>		6403120	MAR 20, 2017	U-451		
>ADD>		6419958	MAR 20, 2017	U-459		
>ADD>		6444708	JUN 28, 2013			
>ADD>		4535186*PED	JUN 13, 2008			
>ADD>		5916923*PED	DEC 28, 2013	U-398		
>ADD>		6274171*PED	SEP 20, 2017			
>ADD>		6403120*PED	SEP 20, 2017	U-451		
>ADD>		6419958*PED	SEP 20, 2013	U-459		
>ADD>		6444708*PED	DEC 28, 2013			
>ADD>	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007	I-325	MAY 02, 2004
>ADD>		6274171	MAR 20, 2017		PED	SEP 02, 2004
>ADD>		5916923	JUN 28, 2013	U-398		
>ADD>		6403120	MAR 20, 2017	U-451		
>ADD>		6419958	MAR 20, 2017	U-459		
>ADD>		6444708	JUN 28, 2013			
>ADD>		4535186*PED	JUN 13, 2008			
>ADD>		5916923*PED	DEC 28, 2013	U-398		
>ADD>		6274171*PED	SEP 20, 2017			
>ADD>		6403120*PED	SEP 20, 2017	U-451		
>ADD>		6419958*PED	SEP 20, 2013	U-459		
>ADD>		6444708*PED	DEC 28, 2013			

PATENT TERM EXTENSION AND NEW PATENTS -December 20, 2002
 DOCKET NUMBER *95S-0117
 *PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	4535186	DEC 13, 2007		I-325 MAY 02, 2004
>ADD>			6274171	MAR 20, 2017		PED SEP 02, 2004
>ADD>			5916923	JUN 28, 2013	U-398	
>ADD>			6403120	MAR 20, 2017	U-451	
>ADD>			6419958	MAR 20, 2017	U-459	
>ADD>			6444708	JUN 28, 2013		
>ADD>			4535186*PED	JUN 13, 2008		
>ADD>			5916923*PED	DEC 28, 2013	U-398	
>ADD>			6274171*PED	SEP 20, 2017		
>ADD>			6403120*PED	SEP 20, 2017	U-451	
>ADD>			6419958*PED	SEP 20, 2013	U-459	
>ADD>			6444708*PED	DEC 28, 2013		
	021119 001	VERTEPORFIN;VISUDYNE	4883790	JAN 20, 2007		
	020388 001	VINORELBINE TARTRATE;NAVELBINE	4307100	JUL 08, 2002		
			4307100*PED	JAN 08, 2003		
	021266 001	VORICONAZOLE;VFEND			NCE	MAY 24, 2007
	021266 002	VORICONAZOLE;VFEND			NCE	MAY 24, 2007
	021267 001	VORICONAZOLE;VFEND			NCE	MAY 24, 2007
	021036 001	ZANAMIVIR;RELENZA	6294572	DEC 15, 2014		
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019		
	020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019		
	020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019		
	020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	6150366	MAY 27, 2019		
	020919 001	ZIPRASIDONE MESYLATE;GEODON	6399777	APR 01, 2017	NCE	FEB 05, 2006
			4831031	MAR 02, 2007	NDF	JUN 21, 2005
			6110918	MAR 26, 2017		
			6232304	APR 01, 2017		
	021223 001	ZOLEDRONIC ACID;ZOMETA			I-361	FEB 22, 2005
	021231 001	ZOLMITRIPTAN;ZOMIG-ZMT	5466699	NOV 14, 2012	NCE	NOV 25, 2002
	020789 001	ZONISAMIDE;ZONEGRAN	6342515	DEC 21, 2018	U-438	